Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toxicity of Allogeneic SCT for Relapsed Ewing Sarcoma
NCT02472392Phase 1Completed
- Sponsor
- University of Louisville
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic hematopoietic stem cells in Ewing sarcoma and rhabdomyosarcoma (RMS) (2 arms), sponsored by University of Louisville. Primary endpoint: Toxicity assessed by safety labs and close monitoring at 5 years. Started Apr 2013; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
Ewing sarcomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT02472392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472392.